Drug Profile
Research programme: anti-TAA monoclonal antibodies - Micromet
Latest Information Update: 19 Mar 2008
Price :
$50
*
At a glance
- Originator Micromet Inc
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 May 2006 Micromet AG has merged with CancerVax Corporation to form Micromet Inc
- 20 May 2004 Preclinical trials in Cancer in USA (Parenteral)